<DOC>
	<DOC>NCT00355238</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Diagnosis of hepatocellular carcinoma (HCC) â‰¥ 2cm based on: Biopsy OR Radiological evidence of HCC by contrastenhanced CT scan or contrastenhanced AND Blood test positive for Hepatitis B or C AND Alpha fetoprotein above &gt; 400 mg/L Not appropriate for curative surgery Screening Blood Pressure &lt;150/100 mmHg, Left Ventricular Ejection Fraction (LVEF) &gt;50% Heart Attack within 12 months, uncontrolled chest pain within 6 months Ascites resistant to diuretic medication therapy Portalsystemic encephalopathy Portal hypertension with bleeding esophageal or gastric varices within the past 2 months Deficiency of sodium in the blood with sodium &lt; 125 mEq/L Subjects with serious nonhealing wounds, ulcers or bone fractures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>